SCD 1 - Tapestry Pharmaceuticals
Alternative Names: SCD-1Latest Information Update: 10 Aug 2005
At a glance
- Originator Tapestry Pharmaceuticals
- Developer The Childrens Hospital of Philadelphia; Thomas Jefferson Medical College
- Class Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sickle cell anaemia
Most Recent Events
- 10 Aug 2005 Discontinued - Preclinical for Sickle cell anaemia in USA (unspecified route)
- 11 May 2004 NaPro BioTherapeutics is now called Tapestry Pharmaceuticals
- 16 Jun 2003 Preclinical trials in Sickle cell anaemia in USA (unspecified route)